Safety and efficacy of inhaled PEG-ADM in ARDS patients : a randomised controlled trial
Karagiannidis, Christian (University Witten/Herdecke (Colònia, Alemanya))
McAuley, Danny F. (Universitat Autònoma de Barcelona. Departament de Medicina)
Thompson, Taylor B. (Harvard Medical School)
Reimer, Thomas (Pharmaceuticals Research & Development (Berlin, Alemanya))
Shakery, Kaweh (Queen's University of Belfast)
Schmitz, Sebastian (Bayer AG (Berlin, Alemanya))
Núñez Cortés, Manuel (Bayer AG (Berlin, Alemanya))
Ullrich, Roman (AUVA Trauma Centre (Vienna, Àustria))
Meziani, Ferhat (Hôpitaux Universitaires de Strasbourg)
Mercat, Alain (Université d'Angers)
Chiumello, Davide (Universidad de Milan)
Duska, Frantisek (Charles University (Praga, República Txeca))
Combes, Alain (Charles University (Praga, República Txeca))

Date:	2025
Description:	9 pàg.
Abstract:	Background This study aimed to evaluate the safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) for the management of acute respiratory distress syndrome in critically ill patients on mechanical ventilation. Methods A Phase 2a/b randomised, double-blind, placebo-controlled multicentre trial was conducted. Patients with acute respiratory distress syndrome were assigned to receive PEG-ADM 960 μg or 1920 μg, or placebo. The primary endpoints were safety, efficacy, and ventilator-free survival at Day 28. Efficacy was assessed using ventilator-free survival and the clinical utility index, a composite endpoint that includes extravascular lung water index, oxygenation index, non-pulmonary Sequential Organ Failure Assessment score. Results Ninety patients were randomised (PEG-ADM 960 μg: n = 29; PEG-ADM 1920 μg: n = 30; placebo: n = 31). Both dosages of PEG-ADM were well tolerated, with adverse event profiles similar to placebo. However, no significant efficacy was observed on the clinical utility index. Ventilator-free survival at Day 28 was lower in the PEG-ADM 960 μg group (52%) compared with the PEG-ADM 1920 μg (67%) and placebo (65%) groups. No significant differences were noted in overall mortality or the need for continued ventilation at Days 28 and 60. Conclusion Inhaled PEG-ADM was well tolerated in patients with acute respiratory distress syndrome, but it did not improve clinical outcomes, which led to the early discontinuation after the first part of the trial for futility. Trial registration ClinicalTrials. gov: NCT04417036 (date of registration: 4 June 2020).
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Critical care, Vol. 29 (2025) , p. 448, ISSN 1466-609X

DOI: 10.1186/s13054-025-05617-y
PMID: 41131549

9 p, 884.0 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles